Internal Server Error

Recursion Pharmaceuticals - About the company

Recursion Pharmaceuticals is a public company based in New York (United States), founded in 2013 by Blake Borgeson and Dean Y Li. It operates as an AI-enabled drug discovery and development platform for novel therapeutics. Recursion Pharmaceuticals has raised $452M in funding from investors like Felicis Ventures, DCVC and Advantage Capital. The company has 252 active competitors, including 80 funded and 15 that have exited. Its top competitors include companies like Schrodinger, Relay Therapeutics and Atomwise.

Company Details

AI-enabled drug discovery and development platform for novel therapeutics. It focuses on identifying new targets and designing optimized molecules. The platform utilizes biological and chemical datasets, machine learning models, and a supercomputer to accelerate the discovery of medicines. It aims to improve the speed and efficiency of drug development for conditions with high unmet needs, including cancers and rare diseases. The company also forms strategic partnerships to expand its impact on patients.
Social
X
Email ID
*****@recursion.com
Phone Number
+1 **********
Registered Address
Salt Lake City, Utah
Key Metrics
Founded Year
2013
Location
New York, United States
Stage
Public
Total Funding
$452M in 19 rounds
Latest Funding Round
Ranked
Annual Revenue
$50M - $100M as on Dec 31, 2025
Employee Count
2 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public

Recursion Pharmaceuticals's IPO details

Recursion Pharmaceuticals got listed on Apr 16, 2021.
Click here to take a look at Recursion Pharmaceuticals's IPO in detail
Sign up to download Recursion Pharmaceuticals' company profile

Recursion Pharmaceuticals's funding and investors

Recursion Pharmaceuticals has raised a total funding of $452M over 19 rounds. Its first funding round was on Jan 01, 2014. Its latest funding round was a Post IPO round on Jul 12, 2023 for $*****. 1 investor participated in its latest round. Recursion Pharmaceuticals has 49 institutional investors.

Here is the list of recent funding rounds of Recursion Pharmaceuticals:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jul 12, 2023
3865985
Post IPO
7772133
3306328
8858977
6800947
Oct 25, 2022
4355260
Post IPO
7563694
6539207
9465574
Sep 09, 2020
4639756
Series D
8890982
9252286
lockAccess funding benchmarks and valuations. Sign up today!

Recursion Pharmaceuticals' founders and board of directors

Founder? Claim Profile
The founders of Recursion Pharmaceuticals are Blake Borgeson and Dean Y Li.
Here are the details of Recursion Pharmaceuticals' key team members:
  • Blake Borgeson: Co-Founder, Board Member of Recursion Pharmaceuticals. They are also an angel investor in 1 startup.
  • Dean Y Li: Co-Founder & Board Member of Recursion Pharmaceuticals.

Recursion Pharmaceuticals' employee count trend

Recursion Pharmaceuticals has 2 employees as of Sep 26. Here is Recursion Pharmaceuticals's employee count trend over the years:
Employee count trend for Recursion Pharmaceuticals
lockUncover Recursion Pharmaceuticals' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Recursion Pharmaceuticals's Competitors and alternates

Top competitors of Recursion Pharmaceuticals include Schrodinger, Relay Therapeutics and Atomwise. Here is the list of Top 10 competitors of Recursion Pharmaceuticals, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Schrodinger
Schrodinger
1990, New York City (United States), Acquired
Provider of a web-based simulation and modelling tool
$162M
74/100
2nd
AI-enabled drug discovery and development platform for novel therapeutics
$452M
64/100
3rd
Logo for Relay Therapeutics
Relay Therapeutics
2016, Cambridge (United States), Public
Developer of drug discovery platform and study protein motion
$520M
70/100
4th
Logo for Atomwise
Atomwise
2012, San Francisco (United States), Series B
Developer of artificial intelligence platform for small molecule drug discovery
$219M
67/100
5th
Logo for Valo Health
Valo Health
2019, Boston (United States), Series B
AI-powered platform for drug discovery and development
$450M
67/100
6th
Logo for XtalPi
XtalPi
2014, Cambridge (United States), Public
AI-based drug research and development company
$785M
67/100
7th
Logo for Isomorphic Labs
Isomorphic Labs
2021, London (United Kingdom), Series B
Digital platform focused on revolutionizing drug discovery using AI
$2.7B
64/100
8th
Logo for Xaira
Xaira
2023, San Francisco (United States), Series D
AI-enabled platform for drug discovery and development
$1B
63/100
9th
Logo for In Silico
In Silico
2014, Boston (United States), Public
AI-enabled bioinformatics platform for drug discovery and biomarker development
$510M
62/100
10th
Logo for Tandem AI
Tandem AI
2021, New York (United States), Series A
AI-based drug discovery tool for researchers
$82M
62/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Recursion Pharmaceuticals's competitors? Click here to see the top ones

Recursion Pharmaceuticals's Investments and acquisitions

Recursion Pharmaceuticals has not made any investments yet. Recursion Pharmaceuticals has made 4 acquisitions.
Here is the list of latest three $acquisitions:lockFilter this list
Date of Investment/Acquisition
Type
Company Name
Founded Year
Location
Aug 08, 2024
Acquisition
2012
May 08, 2023
Acquisition
2013
Toronto (Canada)
May 08, 2023
Acquisition
2017
Montreal (Canada)
lockWant to know more about where corporates are investing? Sign up today!
See all acquisitions by Recursion Pharmaceuticals

Reports related to Recursion Pharmaceuticals

Here is the latest report on Recursion Pharmaceuticals's sector:

News related to Recursion Pharmaceuticals

lockFilter this list
Media has covered Recursion Pharmaceuticals for a total of 24 events in the last 1 year, 9 of them have been about company updates and 4 about people movement.
•
•
Recursion Pharmaceuticals Director Blake Bogeson Receives $100,200Investing•Sep 03, 2026•Recursion Pharmaceuticals
•
Recursion Pharmaceuticals Announces Grant of Inducement AwardsGlobeNewswire•Aug 01, 2026•Recursion Pharmaceuticals
•
Recursion Pharmaceuticals Director Sells $158,500 Worth of StockInvesting•Jul 10, 2026•Recursion Pharmaceuticals
•
Recursion Announces Board TransitionGlobeNewswire•Apr 30, 2026•Recursion Pharmaceuticals
•
•
Altitude Labs Empowers Biotech Founders with Educational Accelerator ProgramBioSpace•Apr 29, 2026•Recursion Pharmaceuticals
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Recursion Pharmaceuticals

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford